Business Wire

Quintiq and the World Food Programme: Working Together towards a World with Zero Hunger

Del

Quintiq, a Dassault Systèmes company and global leader in supply chain planning and optimization, and the United Nations World Food Programme (WFP) announced today a partnership with the objective of optimizing WFP’s global humanitarian supply chain.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160921005532/en/

Established in 1961, WFP is the world’s largest humanitarian agency dedicated to fighting hunger across the globe. Each year, WFP assists around 80 million people in over 80 countries through food and cash-based assistance. WFP has approximately 15,200 staff, many of whom work in remote areas, directly supporting the most vulnerable communities. On any given day, WFP operates an average of 70 aircraft, 40 ocean shipments, and 5,000 trucks. WFP also works with retailers, financial service providers and other local partners to deliver cash and food vouchers. To provide life-saving food assistance to families in need, WFP does whatever it takes – using all means possible, from transport by air, land, sea, and even animals when basic infrastructure is lacking.

Bringing together WFP’s unique understanding of humanitarian supply chains and Quintiq’s expertise in planning and optimization, the partnership will enable WFP to do even more with available resources. Quintiq and WFP deploy new technologies to create the best possible sourcing strategies and logistics networks. By applying world class business solutions to complex social and humanitarian challenges, WFP aims to maximize the impact of its programmes while optimizing costs throughout its supply chains, thereby taking another step towards Zero Hunger.

“Partnerships are crucial to reach a world without hunger,” said Corinne Fleischer, Director of Supply Chain. “At WFP, we run the most reliable, responsive and cost-effective humanitarian operations possible, in order to reach millions of vulnerable families with food assistance each year. We look forward to designing innovative strategies to further optimize WFP’s supply chain, together with our new partner, Quintiq.”

“WFP has the world’s largest humanitarian supply chain puzzle – the scale of their work, the routes that they have to use and the methods they employ to complete deliveries in some of the world’s most unforgiving territories are unlike anything else the logistics industry has ever seen. Further complicating the challenge is the fact that more than 80 million people depend on the assistance that they provide, which demands perfect delivery performance each and every day,” said Quintiq CTO, Wil Lamain.

He added: “WFP has unparalleled experience in managing humanitarian supply chains. Quintiq has proven expertise and experience in optimizing some of the biggest logistics operations and supply chains across the globe. WFP is doing great work. We want to help them become even greater and bring them closer to reaching their Zero Hunger goal.”

In a first for the company, Quintiq will be providing this solution to WFP on a pro bono basis, with fees waived for licenses, IT facilities and consulting hours. The latter will be fully funded through voluntary salary, commission and overtime contributions by Quintiq employees worldwide.

Rob van Egmond, CEO of Quintiq, commented: “At Quintiq, we are passionate about solving supply chain puzzles. What drives our passion is the desire to make a positive difference to people’s lives. As a leader in planning and optimization, we believe we have what it takes to assist the WFP in solving humanity’s greatest supply chain puzzle. We are honoured to be their partner and hope that we can help them to achieve a world without hunger.”

*WFP does not endorse any product or service.

About WFP

WFP is the world's largest humanitarian agency fighting hunger worldwide, delivering food in emergencies and working with communities to build resilience. Each year, WFP assists some 80 million people in around 80 countries.

Follow WFP on Twitter @wfp_media

About Quintiq

Every business has its supply chain planning puzzles. Some of those puzzles are large. Some are complex. Some seem impossible to solve. Since 1997, Quintiq has been solving each of those puzzles using a single supply chain planning & optimization software platform. Today, approximately 12,000 users in over 80 countries rely on Quintiq software to plan and optimize workforces, logistics and production. Part of Dassault Systèmes (Euronext Paris: #13065, DSY.PA), Quintiq has headquarters in the Netherlands and the USA and offices around the world.

For more information, visit www.quintiq.com or follow Quintiq on Twitter, Facebook, LinkedIn and YouTube.

Contact information

North America enquiries
Racepoint Group
Brittany Falconer
Tel: +1 617 624 3242
quintiq@racepointgroup.com
or
EMEA enquiries
Weber Shandwick
Sophie Waterfield
Tel: +44 (0) 207 067 0728
quintiq@webershandwick.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom